319 results on '"Rog, David"'
Search Results
2. Delays in Multiple Sclerosis diagnosis (DIMES): protocol for a multicentre, observational study of multiple sclerosis diagnostic pathways in the United Kingdom and Republic of Ireland
3. Measuring disability in multiple sclerosis: the WHODAS 2.0
4. Reconciling lesions, relapses and smouldering associated worsening: A unifying model for multiple sclerosis pathogenesis
5. Prevalence, treatment and correlates of depression in multiple sclerosis
6. Quantifying the administration and monitoring time burden of several disease-modifying therapies for relapsing multiple sclerosis in the United Kingdom: A time and motion study
7. Ethnic disparities in the epidemiological and clinical characteristics of multiple sclerosis
8. Multiple Sclerosis vision questionnaire (MSVQ-7): Reliability, validity, precision and discrimination
9. Ethnicity and deprivation negatively impact the access to disease-modifying therapy for relapsing-remitting multiple sclerosis: a retrospective, single-centre study
10. Ethnic Disparities in the Incidence and Prevalence of Multiple Sclerosis (P4-6.018)
11. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial
12. The four self-efficacy trajectories among people with multiple sclerosis: Clinical associations and implications
13. University education facilitates uptake of disease-modifying therapies for multiple sclerosis: A community-based study using the UK MS Register
14. Final analysis of 379 pregnancy outcomes after exposure to dimethyl fumarate in a prospective international registry
15. Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study
16. Quality of life in multiple sclerosis is dominated by fatigue, disability and self-efficacy
17. Ethnic disparities in the epidemiological and clinical characteristics of Multiple Sclerosis
18. Interim Analysis of Pregnancy Outcomes After Exposure to Dimethyl Fumarate in a Prospective International Registry
19. Inequalities in access to health and social care among adults with multiple sclerosis: A scoping review of the literature
20. Factors influencing multiple sclerosis disease-modifying treatment prescribing decisions in the United Kingdom: A qualitative interview study
21. Delays in Multiple Sclerosis diagnosis (DIMES): protocol for a multicentre, observational study of multiple sclerosis diagnostic pathways in the United Kingdom and Republic of Ireland.
22. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting
23. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
24. ADAMS project: a genetic Association study in individuals from Diverse Ancestral backgrounds with Multiple Sclerosis based in the UK
25. Final Analysis of Pregnancy Outcomes Following Exposure to Dimethyl Fumarate in a Prospective International Registry (S31.004)
26. Can Autonomous Sensor Systems Improve the Well-being of People Living at Home with Neurodegenerative Disorders?
27. Outpatient neurology diagnostic coding:a proposed scheme for standardised implementation
28. Outpatient neurology diagnostic coding: a proposed scheme for standardised implementation
29. Developing evidence-based guidelines for the safety of symptomatic drugs in multiple sclerosis during pregnancy and breastfeeding: A systematic review and Delphi consensus
30. sj-docx-3-msj-10.1177_13524585221148094 – Supplemental material for Developing evidence-based guidelines for the safety of symptomatic drugs in multiple sclerosis during pregnancy and breastfeeding: A systematic review and Delphi consensus
31. sj-docx-1-msj-10.1177_13524585221148094 – Supplemental material for Developing evidence-based guidelines for the safety of symptomatic drugs in multiple sclerosis during pregnancy and breastfeeding: A systematic review and Delphi consensus
32. sj-docx-2-msj-10.1177_13524585221148094 – Supplemental material for Developing evidence-based guidelines for the safety of symptomatic drugs in multiple sclerosis during pregnancy and breastfeeding: A systematic review and Delphi consensus
33. sj-docx-4-msj-10.1177_13524585221148094 – Supplemental material for Developing evidence-based guidelines for the safety of symptomatic drugs in multiple sclerosis during pregnancy and breastfeeding: A systematic review and Delphi consensus
34. Measuring coping in multiple sclerosis: The Coping Index-MS
35. 151 Updated analysis of pregnancy outcomes for patients with MS in a dimethyl fumarate exposure registry
36. 150 The 70 UK centre multiple sclerosis service and DMT prescribing audit: practical project solutions
37. 135 The UK MS pregnancy register: baseline data from the first fifty enrolled patients
38. 131 Understanding the administration and monitoring time burden of several disease-modifying therapies for relapsing multiple sclerosis
39. Anti-CD20 therapies in pregnancy and breast feeding: a review and ABN guidelines
40. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial
41. Evaluating the feasibility of a real world pharmacovigilance study (OPTIMISE:MS)
42. PO141 Audit of the first line oral disease modifying treatments in greater manchester
43. 1127 Pregnancy outcomes in alemtuzumab trials and registry design
44. “I'm walking into the unknown': Qualitative insights into how emotions and lived experience related to multiple sclerosis diagnosis impact on decisions to pursue disease modifying treatment
45. The impact of smoking cessation on multiple sclerosis disease progression
46. 106 (NOT) comparing apples with apples; MS hospital episode statistics dashboard highlights variation in trusts’ reporting
47. 040 MS disease modifying therapy (DMT) sequencing – natalizumab to cladribine tablets – experience in 20 patients
48. 011 UK variance in DMT advice and prescribing in MS and pregnancy
49. 112 Updated analysis of pregnancy outcomes in a dimethyl fumarate exposure registry
50. Pregnancy outcomes in a dimethyl fumarate exposure registry
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.